Lotus Eye Hospital Files SEBI Reg. 31(4) Substantial Acquisition Disclosure
Under SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, any person acquiring 25% or more of shares or voting rights, or triggering specified thresholds in existing holdings, must disclose within two trading days. Lotus Eye Hospital's filing on or around 19 June 2026 complies with this requirement. The absence of named acquirer details and deal value in public disclosures-combined with no concurrent media coverage or open-offer announcement-suggests the transaction either remains below the 33⅓% open-offer floor or involves a structured acquisition utilising regulatory deferral windows. The specific filing mechanics (disclosure form, filing timestamp, and NSE receipt)…
Why it mattersRegulation 31(4) filing is mandatory within 2 trading days of threshold breach, but the absence of contemporaneous open-offer notice or acquirer ID indicates either a sub-33% stake or a structuring using the 90-day window before open-offer obligation-material for tracking control-change precedent in healthcare M&A.
Counsel—
SectorPharma & Healthcare
[object Object][object Object][object Object][object Object][object Object][object Object][object Object]
Sources
- NSE Archives (PDF) · official
- Bar & Bench
- SEBI Official – SAST Regulations & Master Circular · official
- NSE Listing Regulations · official
Related deals
- Anupam Rasayan India acquires controlling stake in Bliss GVS Pharma; Kanga & Co advises sellers28 Oct 2026
- Fortis Healthcare Limited: Press Release28 Oct 2026 · ₹277 Cr
- Fortis Healthcare Limited: Acquisition28 Oct 2026
- ThinkLaw advises Jagsonpal Pharma on acquiring Group Pharma's wellness portfolio27 Oct 2026
- Mankind Pharma Limited: Scheme of Arrangement26 Oct 2026
- Mankind Pharma Limited: Scheme of Arrangement26 Oct 2026